Nimbus Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $335M
Overview
Uses computational drug discovery to develop small molecules for difficult-to-drug targets.
ImmunologyOncologyMetabolic
Technology Platform
A computational chemistry and structural biology platform for designing small molecules that target allosteric and other challenging binding sites.
Funding History
2Total raised:$335M
Venture$210M
Venture$125M
Opportunities
Its validated platform can be repeatedly applied to new high-value targets across multiple disease areas.
Risk Factors
Reliance on partnership deals for later-stage funding and commercialization exposes it to partner priorities and reduces potential upside.
Competitive Landscape
Competes with other biotechs and large pharma in targeted immunology and oncology, but its computational edge provides differentiation in hitting specific targets.